다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
수면·정신생리 = Sleep medicine and psychophysiology, v.22 no.1, 2015년, pp.5 - 10
이진성 (양산부산대학교병원 정신건강의학과) , 김성곤 (양산부산대학교병원 정신건강의학과) , 김지훈 (양산부산대학교병원 정신건강의학과) , 정우영 (양산부산대학교병원 정신건강의학과) , 박지훈 (양산부산대학교병원 정신건강의학과)
AI-Helper
The secretion of melatonin exhibits a circadian rhythm entrained with the sleep-wake cycle. An alteration of this secretory rhythm has been found in various psychiatric disorders. This review summarizes the regulation of melatonin and its relationship to the circadian rhythm, major depressive disord...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 멜라토닌의 합성 과정에서 작용하는 효소는? | 트립토판(tryptophan)에서 세로토닌(serotonin)이 합성되고, N-아세틸-세로토닌(Nacetyl-serotonin)을 거쳐 멜라토닌이 합성된다. 여기에 작용하는 효소는 트립토판 수산화효소(tryptophan hydroxylase, TPOH), N-아세틸기전달효소(aralkylamine N-acetyltransferase, AA-NAT), O-메틸기전달효소(hydroxyindole-Omethyl transferase, HIOMT)이다. 눈에 들어온 빛 자극은 망막시상하부로(retinohypothalamic tract), SCN, 위목신경절(superior cervical ganglion)을 거쳐 노르에피네프린 시냅스로 송과샘에 이어진다. | |
| 송과샘에서 멜라토닌이 합성되는 과정은? | 멜라토닌은 송과샘에서 합성된다. 트립토판(tryptophan)에서 세로토닌(serotonin)이 합성되고, N-아세틸-세로토닌(Nacetyl-serotonin)을 거쳐 멜라토닌이 합성된다. 여기에 작용하는 효소는 트립토판 수산화효소(tryptophan hydroxylase, TPOH), N-아세틸기전달효소(aralkylamine N-acetyltransferase, AA-NAT), O-메틸기전달효소(hydroxyindole-Omethyl transferase, HIOMT)이다. | |
| 멜라토닌은 어떻게 발견되었나? | 멜라토닌은 1958년 미국의 피부과 의사인 Lerner가 백반증 환자를 연구하던 중 우연히 발견되었다(Srinivasan 등 2006). 백반증 환자들이 피로감과 졸음을 호소하는 것을 관찰하고, 소의 송과샘(pineal glnad)에서 멜라토닌을 추출하였다. |
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C., American Psychiatric Publishing;2013.
Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry 2005; 66 Suppl 9:24-30; quiz 42-23.
Ancoli-Israel S, Ayalon L, Salzman C. Sleep in the elderly: normal variations and common sleep disorders. Harv Rev Psychiatry 2008;16:279-286.
Arendt J. Melatonin: a new probe in psychiatric investigation? Br J Psychiatry 1989;155:585-590.
Bartness TJ, Goldman BD. Mammalian pineal melatonin: a clock for all seasons. Experientia 1989;45:939-945.
Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Morning sunlight reduces length of hospitalization in bipolar depression. J Affect Disord 2001;62:221-223.
Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A, Barbini B, et al. Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry 2003;54:687-692.
Benedetti F, Dallaspezia S, Fulgosi MC, Barbini B, Colombo C, Smeraldi E. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiol Int 2007;24:921-937.
Bersani G, Garavini A. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:185-191.
Brunner P, Sozer-Topcular N, Jockers R, Ravid R, Angeloni D, Fraschini F, et al. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 2006;50:311-316.
Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res 2000;95:43-53.
Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21:700-709.
Delagrange P, Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2006;23:413-418.
Dowling GA, Burr RL, Van Someren EJ, Hubbard EM, Luxenberg JS, Mastick J, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 2008;56:239-246.
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-110.
Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998;55:883-889.
Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L, Fioravanti M, et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000;35:1239-1250.
Fornaro M, McCarthy MJ, De Berardis D, De Pasquale C, Tabaton M, Martino M, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatric Disease and Treatment 2013;9:243-251.
Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012;345:e6664.
Grunhaus L, Hirschman S, Dolberg OT, Schreiber S, Dannon PN. Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. J ECT 2001;17:124-128.
Hallam KT, Olver JS, Chambers V, Begg DP, McGrath C, Norman TR. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006;31:867-875.
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-120.
Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996;63:219-222.
Kennedy SH, Tighe S, McVey G, Brown GM. Melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient. J Nerv Ment Dis 1989;177:300-303.
Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-1732.
Lewy AJ, Nurnberger JI Jr, Wehr TA, Pack D, Becker LE, Powell RL, et al. Supersensitivity to light: possible trait marker for manic-depressive illness. Am J Psychiatry 1985;142:725-727.
Lewy AJ. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol 2007;72:623-636.
Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci U S A 2006;103:7414-7419.
Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P. Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol Int 2001;18:513-524.
Lynch HJ, Ozaki Y, Wurtman RJ. The measurement of melatonin in mammalian tissues and body fluids. J Neural Transm Suppl 1978:251-264.
Mahlberg R, Walther S, Kalus P, Bohner G, Haedel S, Reischies FM, et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging 2008;29:203-209.
Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsater H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008;13:90-98.
Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-291.
Murphy MJ, Peterson MJ. Sleep Disturbances in Depression. Sleep Med Clin 2015;10:17-23.
Nagy AD, Iwamoto A, Kawai M, Goda R, Matsuo H, Otsuka T, et al. Melatonin adjusts the expression pattern of clock genes in the suprachiasmatic nucleus and induces antidepressant-like effect in a mouse model of seasonal affective disorder. Chronobiology International 2015;32:447-457.
Nathan PJ, Burrows GD, Norman TR. Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology 1999;21:408-413.
Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275:31311-31317.
Nurnberger JI Jr, Adkins S, Lahiri DK, Mayeda A, Hu K, Lewy A, et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 2000;57:572-579.
Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85:335-353.
Parry BL, Meliska CJ, Sorenson DL, Lopez AM, Martinez LF, Nowakowski S, et al. Increased melatonin and delayed offset in menopausal depression: role of years past menopause, follicle-stimulating hormone, sleep end time, and body mass index. J Clin Endocrinol Metab 2008;93:54-60.
Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007;190:575-579.
Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011;26:252-262.
Rao AV, Devi SP, Srinivasan V. Urinary melatonin in depression. Indian J Psychiatry 1983;25:167-172.
Sack RL, Lewy AJ, White DM, Singer CM, Fireman MJ, Vandiver R. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry 1990;47:343-351.
Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005;38:10-16.
Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002;32:59-62.
Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003;26:893-901.
Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 2003;38:199-206.
Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, et al. Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138-151.
Terman JS, Terman M, Lo ES, Cooper TB. Circadian time of morning light administration and therapeutic response in winter depression. Arch Gen Psychiatry 2001;58:69-75.
Thorpe M, Pannell J, Nance M. Agomelatine-associated manic switch in bipolar depression: a case report. Aust N Z J Psychiatry 2014;48:958-959.
van Someren EJ, Hagebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, et al. Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry 1996;40:259-270.
Wahlund B, Grahn H, Saaf J, Wetterberg L. Affective disorder subtyped by psychomotor symptoms, monoamine oxidase, melatonin and cortisol: identification of patients with latent bipolar disorder. Eur Arch Psychiatry Clin Neurosci 1998;248:215-224.
Wehr TA, Duncan WC Jr, Sher L, Aeschbach D, Schwartz PJ, Turner EH, et al. A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry 2001;58:1108-1114.
Weitzman ED, Weinberg U, D'Eletto R, Lynch H, Wurtman RJ, Czeisler C, et al. Studies of the 24 hour rhythm of melatonin in man. J Neural Transm Suppl 1978:325-337.
Wetterberg L. Clinical importance of melatonin. Prog Brain Res 1979;52:539-547.
Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5:145-150.
Wirz-Justice A, Quinto C, Cajochen C, Werth E, Hock C. A rapid-cycling bipolar patient treated with long nights, bedrest, and light. Biol Psychiatry 1999;45:1075-1077.
Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011;41:175-184.
Wu YH, Fischer DF, Kalsbeek A, Garidou-Boof ML, van der Vliet J, van Heijningen C, et al. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock". FASEB J 2006;20:1874-1876.
Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007;8:623-636.
Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2007;28:1239-1247.
Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 2015 (DOI: 10.1192/bjp.bp.114.147587).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.